RESUMEN
Between 2016 and 2021, we retrospectively identified 42 patients receiving ≥1 dose of dalbavancin for osteomyelitis, skin and soft-tissue infection, endocarditis or bacteremia, or septic arthritis. Median antibiotic duration prior to dalbavancin administration was 7 days. Within 90 days, 93% achieved clinical cure, 12% were readmitted, 12% developed hepatotoxicity, and 5% died.
RESUMEN
BACKGROUND: The initial availability and distribution of new therapeutic options for outpatients with mild to moderate coronavirus disease 2019 (COVID-19) was limited by insufficient supply, challenges related to administration and dispensing, and unique clinical considerations of each medication. OBJECTIVE: This study aimed to describe the implementation of a standardized process for prescribing, dispensing, and administering medications for outpatients with mild to moderate COVID-19 infection. METHODS: Patients evaluated in outpatient clinics, the emergency department, or urgent care locations who tested positive for COVID-19 with mild to moderate symptoms were candidates for outpatient management. An interdisciplinary team involving physicians from primary care and the emergency department, pharmacists, and nursing developed a standardized note template to gather relevant information before initiating outpatient COVID-19 treatment. Pharmacists reviewed the patients' eligibility for treatment and discussed the available options with providers to facilitate the timely provision of appropriate treatment. RESULTS: A total of 134 outpatients were evaluated for COVID-19 treatment from January 10, 2022, to March 10, 2022. Following a retrospective chart review, it was determined that a medication was administered or dispensed to 80 of those patients. CONCLUSION: Collaboration as an interdisciplinary team allowed for the efficient development of a systematic process in which outpatients with COVID-19 could be evaluated, prescribed, and administered appropriate medications to reduce their risk of disease progression.
Asunto(s)
Tratamiento Farmacológico de COVID-19 , Veteranos , Humanos , Pacientes Ambulatorios , Estudios Retrospectivos , Atención AmbulatoriaRESUMEN
Poster abstracts are evaluated based on the following criteria: significance of the problem to healthy aging or medication management; innovativeness of ideas, methods, and/or approach; methodological rigor of methods and approach; presentation of finding; implications identified for future research, practice, and/or policy; and clarity of writing. Submissions are not evaluated through the peer-reviewed process used by The Consultant Pharmacist. Industry support is indicated, where applicable. Presenting author is in italics. The poster abstract presentation is supported by the ASCP Foundation.
RESUMEN
Multiplex tests for respiratory tract infections include up to 20 targets for common pathogens, predominantly viruses. A specific therapeutic intervention is available for individuals testing positive for influenza viruses (oseltamivir), and it is potentially beneficial to identify non-influenza viruses to avoid unnecessary antibiotic use. We evaluated antimicrobial prescriptions following respiratory pathogen testing among outpatients at a large Veterans Administration (VA) medical center. Results of the FilmArray respiratory panel (BioFire, Salt Lake City, UT) from 15 December 2014 to 15 April 2015 were evaluated among 408 outpatients, and patient medical records were reviewed. Differences in antibiotic and oseltamivir prescription rates were analyzed. Among 408 patients tested in outpatient centers (emergency departments, urgent care clinics, and outpatient clinics), 295 (72.3%) were managed as outpatients. Among these 295 outpatients, 105 (35.6%) tested positive for influenza virus, 109 (36.9%) tested positive for a non-influenza virus pathogen, and 81 (27.5%) had no respiratory pathogen detected. Rates of oseltamivir and antibiotic prescriptions were significantly different among the three test groups (chi-squared values of 167.6 [P < 0.0001] and 10.48 [P = 0.005], respectively), but there was no significant difference in antibiotic prescription rates between the non-influenza virus pathogen group and those who tested negative (chi-square value, 0; P = 1.0). Among adult outpatients, testing positive for influenza virus was associated with receiving fewer antibiotic prescriptions, but no such effect was seen for those who tested positive for a non-influenza virus. These data suggest that testing for influenza viruses alone may be sufficient and more cost-effective than multiplex pathogen testing for outpatients.